Australian regenerative medicine company Orthocell (ASX:OCC) has announced it has completed the first stage of the Remplir US 510(k) market authorisation nerve repair study. …
Orthocell completes all nerve repair surgeries in Remplir US market authorisation study
March 25, 2024 Australian Biotech
Latest Video
New Stories
-
Older Australians given three weeks to have their say on in-home aged care services list
November 3, 2026 - - Latest News -
Diabetes scheme registrations fall as health department points to GLP-1 use
November 3, 2026 - - Latest News -
Report finds 196 missing medicines and billions in unreinvested PBS savings
November 3, 2026 - - Latest News -
Medicines industry faces tough PBS talks, but will it be the most challenging ever?
November 3, 2026 - - Latest News -
Australians with thyroid eye disease gain first PBS subsidised treatment
November 2, 2026 - - Latest News -
‘We are now bridled only by our imagination’. Amgen’s Paul Burton on AI and medicine’s hinge moment
November 2, 2026 - - Latest News -
Edwards Lifesciences opens new Sydney head office as heart valve disease burden grows
November 1, 2026 - - Latest News